Welcome to our dedicated page for OnKure Therapeutics SEC filings (Ticker: OKUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OnKure Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OnKure Therapeutics's regulatory disclosures and financial reporting.
OnKure Therapeutics, Inc. is the issuer of Class A common stock covered in this beneficial ownership report. Investment adviser ADAR1 Capital Management, LLC and its manager Daniel Schneeberger each report beneficial ownership of 2,238,684 shares of Class A common stock, representing 5.5% of the class based on 40,496,309 shares outstanding as of June 30, 2026. These shares include holdings by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and other separately managed accounts for which ADAR1 Capital Management acts as investment manager or sub-adviser.
ADAR1 Capital Management GP, LLC, as general partner of ADAR1 Partners, LP, reports beneficial ownership of 1,832,117 shares, or 4.5% of the class, and this amendment is identified as an exit filing solely for ADAR1 Capital Management GP, LLC as a 5% owner. All reporting persons disclose shared voting and dispositive power over their reported shares and no sole voting or dispositive power.
OnKure Therapeutics, Inc. received an updated ownership report from a group of affiliated investment entities led by Biotechnology Value Fund and Mark N. Lampert. As of June 30, 2026, the group beneficially owned 3,235,778 shares of Class A common stock, representing approximately 8.0% of the 40,395,480 shares outstanding as of May 4, 2026.
The BVF funds and a managed account also hold pre-funded warrants exercisable for 2,147,534 additional shares at an exercise price of $0.0001 per share, subject to a 4.9% beneficial ownership cap that currently prevents any exercise. Various BVF-related entities share voting and dispositive power over these positions, while formally disclaiming beneficial ownership where noted.
Trails Edge Capital Partners, Trails Edge Biotechnology Master Fund and Ortav Yehudai report their beneficial ownership of OnKure Therapeutics, Inc. Class A Common Stock as of June 30, 2026. They collectively may be deemed to beneficially own 1,438,456 shares, representing 3.6% of the outstanding shares, all held directly by Trails Edge Biotechnology Master Fund. The percentage is based on 40,395,480 shares outstanding as of May 4, 2026. Each filer has sole voting and dispositive power over these shares and confirms ownership of 5 percent or less of the class.
OnKure Therapeutics, Inc. director Isaac Manke filed an amended ownership report reflecting a stock option holding rather than a transaction. The amendment states that a previously reported disposition and corresponding acquisition of an option to purchase 15,300 shares of Class A Common Stock in connection with an Option Repricing did not occur. The filing instead reports a stock option, exercisable at $18.20 per share, covering 15,300 underlying shares and expiring on October 3, 2034. According to the vesting schedule, 1/36 of the option vested on November 4, 2024 and 1/36 continues to vest monthly, contingent on continued service.
OnKure Therapeutics, Inc. approved an option repricing effective August 7, 2026, resetting the exercise price of certain underwater employee and consultant stock options granted before January 1, 2025 to $4.14 per share, the Class A common stock closing price on the effective date. The change covers approximately 1.7 million shares with prior exercise prices at or above $10.00, including sizeable grants held by the CEO, CMO, and CFO. Vesting schedules, terms, and share counts are unchanged, and a retention requirement of 18 months for senior management and one year for other participants applies; exercising before meeting this requirement triggers a premium exercise price equal to the original strike. The board states the structure is intended to refresh performance and retention incentives while avoiding additional stock dilution or cash compensation costs.
OnKure Therapeutics, Inc. reported that director Edward T. Mathers received a grant of 22,350 stock options on August 7, 2026. The options carry an exercise price of $4.14 per share and are exercisable for Class A Common Stock. All of the shares subject to the option vest on the earlier of June 4, 2027 or the day prior to the company's next annual meeting of stockholders, subject to his continued service, and expire on August 6, 2036. Following this grant, he holds 22,350 derivative securities of this type directly.
OnKure Therapeutics, Inc. reported that director Liam Ratcliffe received a grant of 22,350 stock options, each representing the right to buy one share of Class A Common Stock at an exercise price of $4.14 per share. All 22,350 options will vest on the earlier of June 4, 2027 or the day prior to the company’s next annual meeting of stockholders, subject to his continued service. Following this grant, Ratcliffe holds 22,350 derivative securities of this option award, which is scheduled to expire on August 6, 2036.
OnKure Therapeutics, Inc. director Andrew John Phillips received a grant of stock options covering 22,350 shares of Class A common stock at an exercise price of $4.14 per share. The options expire on August 6, 2036 and vest 100% on the earlier of June 4, 2027 or the day prior to the company’s next annual meeting of stockholders, contingent on his continued service. Following this award, he holds options on 22,350 shares.
OnKure Therapeutics director Isaac Manke reported equity compensation and option repricing activity involving stock options for Class A Common Stock. On August 7, 2026 he received a grant of 300,000 stock options with an exercise price of $4.14 per share, expiring on August 6, 2036. One quarter of these options vests on February 24, 2027 and the remainder vests in equal monthly installments over the following 36 months, contingent on continued service. On the same date, 15,300 options with an original exercise price of $18.20 per share expiring October 3, 2034 were returned to the issuer and replaced with 15,300 repriced options at an exercise price of $4.14, with the same vesting and expiration. Under the company’s one-time Option Repricing program, if any repriced option is exercised before the end of a defined retention period, the holder must pay the original higher exercise price instead of $4.14.
OnKure Therapeutics, Inc. reported that director Valerie Malyvanh Jansen received a grant of a stock option covering 22,350 shares of Class A common stock. The option has an exercise price of $4.14 per share and expires on August 6, 2036. According to the terms, 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to OnKure’s next annual meeting of stockholders, conditioned on her continued service as a provider through the applicable vesting date. Following this award, she holds 22,350 stock options directly.